Natera, Inc. (NTRA) Q1 2025 Earnings Call

Investor webinar replay

Watch the replay and follow the connected company analysis, news, and investor updates for Natera, Inc..

Watch the replay

Replay transcript excerpt

WEBVTT 00:00:00.031 -- 00:00:03.615 Thanks, operator. Good afternoon. Thank you for joining our conference call to discuss 00:00:03.615 -- 00:00:08.440 the results of our first quarter of 2025. On the line, I'm joined by Steve Chapman, our 00:00:08.440 -- 00:00:13.365 CEO, and Salman Machkevich, President, Clinical Diagnostics. 00:00:13.365 -- 00:00:17.289 Ash Leshin, General Manager of Oncology, will be available for Q&A. 00:00:17.289 -- 00:00:20.852 Today's conference call is being broadcast live via webcast. 00:00:20.852 -- 00:00:25.535 We will be referring to a slide presentation that has been posted to investor.meterra.com. 00:00:25.613 -- 00:00:31.179 A replay of the call will also be posted to our IR website as soon as it's available. 00:00:31.179 -- 00:00:34.903 Starting on slide two, during the course of this conference call, we will be making forward-looking 00:00:34.903 -- 00:00:38.487 statements regarding future events and our anticipated future performance, such as our 00:00:38.487 -- 00:00:41.891 operational and financial outlook and projections, our assumptions for that outlook, 00:00:41.891 -- 00:00:45.916 market size, partnerships, clinical studies, and expected results, opportunities and 00:00:45.916 -- 00:00:49.800 strategies, and expectations for various current and future products, including product 00:00:49.800 -- 00:00:53.264 capabilities, expected release dates, reimbursement coverage, and related effects on 00:00:53.264 -- 00:00:56.902 our financial and operating results. We caution you that such statements reflect our 00:00:56.902 -- 00:01:00.706 best judgment based on factors currently known to us and that actual events or results 00:01:00.706 -- 00:01:04.470 could differ materially. Please refer to the documents we filed from time to time ...